Abstract 80P
Background
The standard treatment for glioblastoma multiforme involves surgery followed by temozolomide (TMZ) treatment. However, many patients develop TMZ resistance either due to autophagic clearance of unwanted materials or reversal of TMZ-induced DNA alterations by methyl guanine o-methyl transferase. Additionally, other drugs are often ineffective because they cannot cross the blood-brain barrier (BBB). Hence, our objective is to repurpose FDA-approved drugs capable of crossing BBB and regulating autophagic pathways.
Methods
We identified differentially expressed genes regulating cellular processes in GBM, and used the Connectivity-MAP (C-Map) database to identify potential drugs, capable of reversing differentially expressed autophagy-associated genes. Following in-silico screening, we conducted cytotoxicity assays with selected drugs to evaluate IC50 values of drugs in 2-D and 3-D models. Additionally, immunoblotting and IF were performed to examine protein expression. Furthermore, we employed MDC staining to identify autophagic vacuoles, Annexin-PI to quantify apoptotic cells.
Results
Analysing GEO dataset, we identified top 10 dysregulated genes. Most downregulated genes were calcium signaling, while upregulated ones were PI3-Akt pathway. After identifying key genes and associated pathways, we used C-Map to identify top 5 drugs with high connectivity scores and BBB penetrance. They were assessed in vitro for their potential against GBM. Among them, Doxylamine and Gemfibrozil exhibited the best cytotoxicity, surpassing the standard drug TMZ. These drugs also hindered autophagic flux, verified by increased p62 and LC3B II proteins. Overexpression of PERK and CHOP confirmed ER stress-induced apoptosis. Furthermore, inhibition of Calmodulin, Calreticulin, and Calnexin post-drug-stress influenced the calcium signaling pathway. AnnexinV-PI assay demonstrated that increased ER stress and subsequent restriction of autophagic flux led to cell death.
Conclusions
Our research highlighted that doxylamine and gemfibrozil could serve as potential alternatives to TMZ for inducing apoptosis, by inhibiting autophagy, inducing ER stress, and generating ROS.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Indian Council of Medical Research (ICMR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract